Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Boehringer Ingelheim acquires Global Stem cell Technology
Boehringer Ingelheim acquires Global Stem cell Technology, Belgian veterinary biotech company, to strengthen its stem cell capabilities in Animal Health